Marker Therapeutics, Inc. financial data

Symbol
MRKR on Nasdaq
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
18 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 585% % 12%
Debt-to-equity 21% % -13%
Return On Equity -81% % 11%
Return On Assets -67% % 8.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16,673,127 shares 56%
Common Stock, Shares, Outstanding 16,700,000 shares 56%
Entity Public Float $17,312,000 USD -64%
Common Stock, Value, Issued $16,672 USD 56%
Weighted Average Number of Shares Outstanding, Basic 15,310,308 shares 70%
Weighted Average Number of Shares Outstanding, Diluted 15,310,308 shares 70%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $11,799,154 USD -12%
General and Administrative Expense $4,184,806 USD -1.3%
Operating Income (Loss) $12,890,426 USD -16%
Net Income (Loss) Attributable to Parent $12,163,620 USD -13%
Earnings Per Share, Basic -0.79 USD/shares 34%
Earnings Per Share, Diluted -0.79 USD/shares 34%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $16,068,048 USD -16%
Other Assets, Current $2,000 USD
Assets, Current $19,070,997 USD -13%
Assets $19,070,997 USD -13%
Accounts Payable, Current $793,727 USD -26%
Employee-related Liabilities, Current $87,083 USD 0.85%
Liabilities, Current $2,274,183 USD -34%
Liabilities $2,274,183 USD -34%
Retained Earnings (Accumulated Deficit) $459,180,798 USD -2.7%
Stockholders' Equity Attributable to Parent $16,796,814 USD -9.5%
Liabilities and Equity $19,070,997 USD -13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,499,737 USD -43%
Net Cash Provided by (Used in) Financing Activities $49,096 USD -92%
Common Stock, Shares Authorized 30,000,000 shares 0%
Common Stock, Shares, Issued 16,700,000 shares 56%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17,042,847 USD -11%
Deferred Tax Assets, Valuation Allowance $43,325,798 USD 5.7%
Deferred Tax Assets, Gross $43,325,798 USD 5.7%
Deferred Tax Assets, Operating Loss Carryforwards $40,896,185 USD 33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $475,960,940 USD 2.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $537,540 USD 119%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%